Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer: Mono-L-aspartyl chlorin e6

Retina

Volumn 21, Issue 5, 2001, Pages 499-508

  Mori, Keisuke ^a   Yoneya, Shin ^a   Anzail, Kaname ^a   Kabasawa, Sho ^a   Sodeyama, Takeo ^a   Peyman, Gholam A ^b   Moshfeghi, Darius M ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Photodynamic therapy; Photosensitizer; Primate model

Indexed keywords

CHLORINE DERIVATIVE; MONO LEVO ASPARTYL CHLORIN E6; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL DEATH; CHOROID; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON MICROSCOPY; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; HYDROPHILICITY; INDOCYANINE GREEN ANGIOGRAPHY; LASER; MACACA; MICROCIRCULATION; NONHUMAN; PHOTODYNAMIC THERAPY; PIGMENT CELL; PIGMENT EPITHELIUM; RETINA; RETINA BLOOD VESSEL; SUBRETINAL NEOVASCULARIZATION;

EID: 0034798770     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200110000-00013     Document Type: Article

References (24)

1. How does photodynamic therapy work?
2. The effect of photodynamic therapy on the microcirculation
3. The endothelium and red blood cells as potential targets in PDT-induced vascular stasis
4. Photodynamic therapy: Effect on the endothelial cell of the rat aorta
5. Vascular damage during PDT as monitored in the chick chorioallantoic membrane
6. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2)
7. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of retreatments in a phase 1 and 2 study
8. Photodynamic therapy with subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin one-year results of 2 randomized clinical trials - TAP report 1
9. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-apartyl chlorin e6)
10. Fluorescence properties of a hydrophilic sensitizer in pigmented rats, rabbits, and monkeys
11. Problems with and pitfalls of photodynamic therapy
12. Threshold and retreatment parameters of NPe6 photodynamic therapy in retinal and choroidal vessels
13. Threshold power levels for NPe6 photodynamic therapy
14. Cutaneous phototoxicity of NPe6 in man
15. Determinants of localization by second-generation PDT sensitizers
16. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model
17. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents
18. In vitro characterization of monoaspartyl chlorin e6 and diaspartyl chlorin e6 for photodynamic therapy
19. In vitro photosensitization I: Cellular uptake and subcellular localization of mono-L-aspartyl chlorin e6, chloro-aluminum sulfonated phthalocyanine, and Photofrin II
20. In vitro photosensitization II: An electron microscopy study of cellular destruction with mono-L-aspartyl chlorin e6 and Photofrin II
21. Subretinal neovascularization: Natural history of an experimental model
22. Lutetium texaphyrin (Lu-Tex): A potential new agent for ocular fundus angiography and photodynamic therapy
23. Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative